<DOC>
	<DOCNO>NCT02705612</DOCNO>
	<brief_summary>The purpose phase II trial determine feasibility efficacy nimotuzumab injection combine concurrent chemoradiotherapy initially inoperable locally advanced cervical cancer .</brief_summary>
	<brief_title>Phase II Clinical Trial Concurrent Chemoradiotherapy Combined Nimotuzumab Stage IIB-IVA Cervical Cancer</brief_title>
	<detailed_description>For locally advanced cervical cancer , radical radiation concurrent chemotherapy remain standard treatment recommend NCCN . However , 35 % case , tumor persistence recurrence metastasis would occur chemoradiation . Nimotuzumab , belong anti-EGFR monoclonal antibody , prove useful multiple solid tumor , NPC , colorectal cancer , etc . In recent year , nimotuzumab also apply recurrence metastasis cervical cancer . It prove well tolerate might role treatment advance cervical cancer . However , publication nimotuzumab use locally advanced cervical cancer .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 Years 70 Years，female Histological diagnosis squamous cell carcinoma cervix , FIGO stage IIBIVA , diameter 46 cm , without distant metastasis . chance surgery confirm two deputy chief doctor gynecology . Moderate high expression EGFR The function main organ normal , include blood , heart , lung , liver , kidney . Without history hypertension , stroke . Blood pressure normal treatment . WBC≥3.5×10E9/L，ANC≥1.5×10E9/L；HB≥90g/L，PLT≥100×10E9/L ALT , AST Cr 1.5 time normal level Willing accept treatment Ability comply trial requirement KPS≥70 Evidence distance metastasis Impossible measure diameter tumor , tumor huge ( diameter &gt; 6cm ) Could n't examine pelvic MRI due variety reason Used treat radiotherapy chemotherapy molecular target therapy immune therapy Diagnosed another malignant tumor 5 year Used volunteer clinical trial . Used allergic reaction grade 3 4 degree experimental drug Severe medical history lung , liver , kidney heart . Active infection part whole body . Examination result show radiotherapy contraindication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>nimotuzumab</keyword>
</DOC>